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AMP-activated protein kinase (AMPK) monitors
cellular energy, regulates genes involved in ATP syn-
thesis and consumption, and is allosterically acti-
vated by nucleotides and synthetic ligands. Analysis
of the intact enzyme with hydrogen/deuterium ex-
change mass spectrometry reveals conformational
perturbations of AMPK in response to binding of
nucleotides, cyclodextrin, and a synthetic small
molecule activator, A769662. Results from this
analysis clearly show that binding of AMP leads to
conformational changes primarily in the g subunit
of AMPK and subtle changes in the a and b subunits.
In contrast, A769662 causes profound conforma-
tional changes in the glycogen binding module of
the b subunit and in the kinase domain of the a
subunit, suggesting that the molecular binding site
of the latter resides between the a and b subunits.
The distinct short- and long-range perturbations
induced upon binding of AMP and A769662 suggest
fundamentally different molecular mechanisms for
activation of AMPK by these two ligands.
INTRODUCTION
Mammals use energy derived from the oxidation of carbon pre-
sent in food sources to generate ATP from ADP. However, the
balance between energy-storing and energy-consuming pro-
cesses in the body is constantly changing, and the ability to
sense changes in energy stores is essential for survival and
thus evolutionarily conserved (Kahn et al., 2005). Classic genetic
experiments in lower eukaryotes demonstrate that the AMP-
activated protein kinase (AMPK) is a critical sensor of energy
stores (Celenza and Carlson, 1984; Momcilovic et al., 2006;
Schimmack et al., 2006). At times of metabolic stress such as
during exercise, hypoxia, and cell proliferation, AMPK becomes
activated in response to the increased AMP:ATP ratio resulting
from higher ATP consumption (Carling et al., 2012; Hardie
et al., 2011, 2012; Johnson et al., 2010; Oakhill et al., 2012;1942 Structure 21, 1942–1953, November 5, 2013 ª2013 Elsevier LtdSteinberg and Kemp, 2009). As a result, AMPK is widely appre-
ciated as a critical metabolic regulator and hence is an attractive
target for the treatment of metabolic diseases. In particular,
AMPK has been shown to play a role in life-span extension in
response to calorie restriction and mediates glucose flux in
cells. AMPK partially mediates the metabolic action of the anti-
diabetes drug metformin, as well as those of compounds with
known anticancer properties such as resveratrol (Hwang et al.,
2009; Vingtdeux et al., 2011). This latter finding has implications
for cancer research, and recent studies show that AMPK is
involved in basic cellular processes such as growth and pro-
liferation, inflammation, autophagy, and maintenance of cell
polarity (Chen et al., 2011; Marx et al., 2010; Mihaylova and
Shaw, 2011; Shang and Wang, 2011).
In muscle, activation of AMPK stimulates fatty acid oxidation,
mitochondrial biosynthesis, and glucose uptake while the
precise role of AMPK activation in liver has been controversial.
Activation of AMPK also results in inhibition of de novo synthesis
of fatty acid in adipose tissue and liver. Physical exercise has
also been shown to activate AMPK in heart (Cacicedo et al.,
2011) andmuscle (Itani et al., 2003). Given the increasingly global
epidemic of obesity and diabetes, the biomedical community
has been seeking novel pharmacological targets for therapeutic
intervention.
Mammalian AMPK is a 134–150 kDa heterotrimeric complex
composed of a catalytic a subunit that harbors a protein kinase
module (two isoforms) and regulatory b (two isoforms) and g
(three isoforms) subunits, each of which is encoded by a sepa-
rate gene. The b subunit is considered a scaffolding subunit
and contains a glycogen binding module (GBD). The g subunit
contains four nucleotide-binding sites across two Bateman
domains (Zhu et al., 2011). AMPK is in part regulated by allosteric
binding of small-molecule ligands that induce conformational
changes and control the phosphorylation state of a threonine
residue in the activation loop, an event that switches on the
enzymatic activity of AMPK. The nucleotide binding sites can
bind AMP, ADP, or ATP and mediate effects on either allosteric
activation or protection from dephosphorylation of its activation
loop phospho-threonine. Although one of these sites (site 4) was
previously believed to be a nonexchangeable AMP site, recent
work has revealed that ATP can also bind with functional con-
sequences (Chen et al., 2012). The structure of each of the
subunits is evolutionarily conserved (Hardie, 2007).All rights reserved
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Allosteric Modulation of AMPK Detected by HDXOur knowledge of the regulation of AMPK activity has been
greatly improved by the availability of yeast and mammalian
AMPK crystal structures (Chen et al., 2012, 2013; Koay et al.,
2010; Rudolph et al., 2010; Xiao et al., 2007, 2011; Zhu et al.,
2011). These structures have revealed that the C-terminal
portion of the b subunit serves as a structural anchor that
holds together the g subunit and the C-terminal region of the
a subunit as a rigid ‘‘core’’ module (Xiao et al., 2007). The
kinase domain of the a subunit adopts a typical protein kinase
fold and is somewhat isolated from the remainder of the struc-
ture except for the close interactions formed by its activation
loop (Xiao et al., 2011). The precise details of the conformation
and the location of the intervening polypeptide segment
between the kinase module and the C-terminal portion of the
a subunit have recently been challenged (Chen et al., 2013).
In addition, the location of glycogen binding module of the
b subunit in mammalian AMPK structures is still unknown.
While models have been proposed for the molecular mecha-
nism responsible for AMPK activation by AMP, the dynamics
of communication among the subunits are largely unknown,
as are the details of the conformational changes induced by
adenine nucleotides.
AMPK has a selected pool of cellular targets in adipose tissue,
liver, heart, muscle, kidney, and brain (reviewed in Hardie, 2007).
During times of low energy reserves, AMPK inhibits cell growth
and the biosynthesis of proteins, lipids, and carbohydrates, while
also stimulating catabolic processes that generate ATP. AMPK
is activated by phosphorylation mediated by upstream kinases,
LKB1 (Hawley et al., 2003), and CaMKKb (Hawley et al., 2005;
Hurley et al., 2005). Although it has been reported that AMPK
could be activated by TAK1, the physiological role of this is not
well understood (Momcilovic et al., 2006). Once activated,
AMPK mediates rapid cellular responses to alterations in
systemic energy status by phosphorylating downstream tran-
scription factors, enzymes, and coactivators. Given the role of
AMPK in cellular metabolism, structural insights into the mecha-
nisms of AMPK activation could inform the design of AMPK-
specific drugs for the treatment of diseases such as diabetes
and obesity. Several indirect AMPK activators have already
been reported such as biguanide (metformin) and thiazolidine-
diones (rosiglitazone), which are used to treat type 2 diabetes
(Fryer et al., 2002); natural products such as resveratrol, cate-
chins, theaflavins, and triterpinoids are also known to activate
AMPK indirectly by elevation of AMP levels. In addition, Cool
and colleagues have reported direct activation of AMPK by
compounds belonging to the thienopyridone chemical scaffold
exemplified by A769662 (Cool et al., 2006). Since then, studies
from several laboratories have suggested that the mechanism
of AMPK activation by A769662 is likely to be very different
from that by AMP (Scott et al., 2008). Pang and colleagues
have reported the discovery of another class of direct AMPK
activators represented by PT1 that is believed to target the a
subunit (Pang et al., 2008). A recent review article on the
AMPK patent literature describes a number of other small
molecule ligands that directly activate AMPK (Giordanetto and
Karis, 2012).
Previously, we have applied hydrogen/deuterium exchange
(HDX) coupled with mass spectrometry to classify selective
estrogen receptor a modulators (SERMS) and correlate theStructure 21, 1942–19HDX signatures of each ligand class with their pharmacological
effects (Dai et al., 2008) and have used HDX to characterize
the protein-ligand interaction of other nuclear hormone recep-
tors such as PPARg (Bruning et al., 2007; Choi et al., 2010,
2011) and VDR-RXR (Zhang et al., 2011). Previous solution
X-ray scattering studies suggested conformational changes of
AMPK heterotrimer induced by the binding of AMP (Riek et al.,
2008). In addition, recent crystal structures of the AMPK core
complex show that nucleotide binding can lead to changes in
the conformation of the Bateman domains in the g subunit
(Chen et al., 2012; Xiao et al., 2007). This alteration of the
structure likely involves positional changes in the a and b sub-
units outside the core complex, but this has not been confirmed.
In this study, we use HDX-MS technique to investigate the
conformational mobility of the kinase and dynamics of subunit
communication during the binding of small molecule ligands to
AMPK. In addition, the effect of phosphorylation of the threonine
residue in the activation loop on the conformational mobility of
the kinase was also monitored. The results of these combined
methods show that while binding of AMP causes primarily
conformational changes in the g subunit with subtle effects
on the a and b subunits, significant stabilization of the GBD of
the b subunit and the kinase module of the a subunit occur
upon binding of A769662. These studies also suggest that the
molecular binding site of A769662 is located between the GBD
of the b subunit and the kinase module of the a subunit and
reveal distinct patterns of long-range conformational changes
induced by binding of A769662 and AMP.
RESULTS
Sequence Coverage of 134 kDa Trimeric AMPK a1b1g1
A bottom-up approach to AMPK was first investigated by
optimizing conditions for protein digestion. Figure S1A (avail-
able online) shows the tandem mass spectrometry (MS/MS)
sequence coverage obtained for each subunit of the hetero-
trimer. Highlighted in yellow are the areas included in the
chimeric structure of AMPK (Protein Data Bank [PDB] ID:
2Y94), which represents the most complete AMPK structure
known (Xiao et al., 2011). Also, highlighted in red are key sites
of phosphorylation. Because the 2Y94 structure lacks the
glycogen-binding domain of the b subunit (GBD, amino acids
77–156), we constructed a chimeric atomic model of mamma-
lian AMPK composed of the 2Y94 structure along with the
GBD based on its known position in the yeast AMPK structure
(Amodeo et al., 2007). We have mapped our HDX results onto
this chimeric model throughout the paper. The three-dimen-
sional representations of these two structures are shown in Fig-
ure S1B. The percent sequence coverage for each subunit
under MS/MS, t0, and on-exchange experimental conditions,
are provided in Figure S1C. Under MS/MS conditions, the
coverage for the a, b, and g subunits are 80%, 98%, and
95%; under t0 conditions, the coverage is 78%, 95%, and
91%; and under on-exchange conditions, the coverage is
70%, 82%, and 81%, respectively. A decrease in sequence
coverage is expected for on-exchange due to increased overlap
of peaks caused by expanding isotopic envelopes with
increasing amounts of deuterium; however, the sequence
coverage is substantial for a 134 kDa protein.53, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1943
Figure 1. Dynamics of apo AMPK a1b1g1
(A) The percentage of corrected deuterium uptake for all peptides of apo AMPK is mapped onto PDB 2Y94. A separate model of GBD is built based on yeast
AMPK structure and shown alongside 2Y94. Three different time points (10, 300, and 3,600 s) are shown here. The percentage of deuterium uptake values, an
average of six time points (0 s to 3,600 s), is depicted by color code explained at the bottom of the figure. Regions colored as white represent peptides that are not
consistently resolved in the study.
(B) Deuterium uptake curve of Ca helix from kinase domain. These plots present the level of deuterium incorporation (%D) for a given peptide across all time points
for three replicates in two sample conditions. The individual replicatemeasurements at each time point are used to calculate and plot themean%D. The error bars
represent the SD of these measurements.
(C andD) Differential deuterium uptake of phosphorylated and nonphosphorylated peptide spanning the activation loop of the a subunit (C) and the Ser108 loop of
the b subunit (D). These plots present the level of deuterium incorporation (%D) for a given peptide across all time points for three replicates in two sample
conditions. The individual replicate measurements at each time point are used to calculate and plot the mean %D. The error bars represent the SD of these
measurements.
(E) Peptides belonging to two different CBS motifs of the g subunit show different levels of deuterium incorporation. These plots present the level of deuterium
incorporation (%D) for a given peptide across all time points for three replicates in two sample conditions. The individual replicate measurements at each time
point are used to calculate and plot the mean %D. The error bars represent the SD of these measurements.
See also Figures S1 and S2.
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We investigated the conformational dynamics that occur over
time in the heterotrimer prior to the addition of any exogenous
ligand (Figure 1A). The a subunit has a highly dynamic helix
(Figure 1B) from residues 60–70 (KIRREIQNLKL), which corre-
sponds to the Ca helix of protein kinases. The Ca helix is a
well-known regulatory module in protein kinases that controls
their activation states. We also observed substantial perturba-
tion of the DFG motif (highly conserved region consisting of
characteristic aspartic acid, phenylalanine and glycine residues
immediately N terminal to the activation loop) involved in inhi-
bitor and substrate binding. A peptide spanning the activation
loop (170–189: LRTSCGSPNYAAPEVISGRL), which includes1944 Structure 21, 1942–1953, November 5, 2013 ª2013 Elsevier Ltdthe threonine residue important for enzyme activation, T172,
exhibits differences in dynamics based upon its phosphoryla-
tion. As seen in the build-up curves for each peptide (Figure 1C),
the extent of deuterium incorporation is consistently less in
the phosphorylated peptide compared to that in the nonphos-
phorylated peptide, implying restricted dynamics of the former.
The mass spectral population of the phosphorylated peptide
is roughly 30-fold greater than the nonphosphorylated peptide
consistent with the previous mass spectra data, suggesting
that the vast majority of the protein is in the activated (phos-
phorylated) state (Figure S2). Similar behavior is observed
for a peptide in the b subunit (101–112: SKLPLTRSHNNF)
that contains a key serine residue, S108. The phosphorylatedAll rights reserved
Figure 2. Effect of AMP and ZMP on AMPK a1b1g1
(A) Differential HDX data mapped onto the AMPK atomic structure (PDB 2Y94)
(B) Schematic representation of AMPK regions undergoing conformational changes upon AMP/ZMP binding. Percentages of deuterium differences are
color-coded according to the color key. The boxed area in the activation loop region represents the phosphorylated form as compared to the non-boxed area
below that represents the nonphosphorylated form.
See also Tables S1 and S2.
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Allosteric Modulation of AMPK Detected by HDXpeptide exhibits a lower degree of deuterium incorporation
(Figure 1C) and the mass spectral population was approximately
10-fold greater than the nonphosphorylated peptide (data not
shown).
In addition to the aforementioned effects on the a and b
subunits, we also observed significant changes in the dynamics
of two cystathionine beta-synthase (CBS) motifs in the g
subunit responsible for AMP binding. The antiparallel beta
sheets spanning residues 228–243 are known to comprise an
exchangeable AMP binding site (site 3—the revised nomen-
clature from–(Kemp et al., 2007) to match the nucleotide bind-
ing sites 1–4 with the CBS motifs 1–4) and show a high rate
of deuterium incorporation across all time points indicating
very dynamic behavior (Figure 1E). In contrast, an adjacent
set of antiparallel beta sheets spanning residues 298–315
(site 4) that is known to be a tight (weakly exchangeable)
nucleotide binding site show a much slower rate of deuterium
incorporation consistent with this region being much less
dynamic. Taken together, the observations regarding the
dynamics of these two AMP-binding sites are consistent withStructure 21, 1942–19their purported functions and with crystallographic and muta-
tional studies (Chen et al., 2012; Oakhill et al., 2010; Xiao
et al., 2011).
Allosteric Effect of AMP/ZMP on AMPK a1b1g1
Conformational Dynamics
We next studied the allosteric effects of AMP/ZMP binding on
AMPK conformational dynamics. In these studies, we observed
that the binding of AMP to the heterotrimer induced protection
from solvent exchange in the Ca -helix (60–70) and auto-inhibi-
tory domain (288–298) of the a subunit compared to the unli-
ganded enzyme (Figure 2; Table S2). Similarly, upon binding of
AMP, a peptide from the C-terminal region of the b subunit
(224–240) also exhibited increased protection from deuterium
exchange. Moreover, significant protection from solvent ex-
change was also observed for the activation loop peptide that
harbors the phosphorylated T172 (Table S1). The largest change
in deuterium protection pattern caused by AMP was observed in
the g subunit. As shown in Figure 2B, AMP binding causes sig-
nificant protection of peptides from the CBS 3 and 4 motifs.53, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1945
Figure 3. Conformational Changes of AMPK a1b1g1 upon Binding of A769662, Beta-Cyclodextrin, and Staurosporine
(A) Differential HDX data mapped onto the AMPK atomic structure (PDB 2Y94).
(B) Schematic representation of AMPK regions undergoing conformational changes upon binding of A769662, b-cyclodextrin, and staurosporine. Percentages of
deuterium differences are color-coded according to the color key. The boxed area in the activation loop region represents the phosphorylated form as compared
to the nonboxed area below that represents the nonphosphorylated form.
See also Figure S3 and Tables S1 and S2.
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Allosteric Modulation of AMPK Detected by HDXPeptides around site 3 (228–243) show greater protection
compared to peptides around the weakly exchangeable site 4
(298–315). Also, binding of AMP leads to protection of peptides
around the CBS 1 and 2 motifs.
A similar protection pattern was observed in the auto-inhib-
itory domain of the a subunit upon binding of ZMP, an AMP
analog and a cellular metabolite of AICAR. Binding of ZMP
causes only very little perturbations in the b subunit, consistent
with the observations with AMP. As expected, the largest ef-
fect of ZMP binding was observed in the g subunit with greater
protection seen in the exchangeable site 3 when compared to
the weakly exchangeable site 4. However, the degree of pro-
tection is less than that observed following binding of AMP
(Figures 2A and 2B; Table S2). AMP and ZMP were added at
50-fold molar excess (500 mM) compared to 10-fold molar
excess of other ligands as AMP affinities for the two readily
exchangeable sites (sites 1 and 3) have been reported in the
range of 2–80 mM (Xiao et al., 2011). However, it is clear
from the HDX perturbation fingerprints of AMPK bound to
either AMP or ZMP that both ligands display tight binding in
the g subunit that triggers allosteric communication across
the other subunits.1946 Structure 21, 1942–1953, November 5, 2013 ª2013 Elsevier LtdEffect of A769662, Beta-Cyclodextrin,
and Staurosporine Binding to AMPK a1b1g1:
Investigation of an Activator Binding Site
In an effort to understand the mechanism of action of the small
molecule AMPK activator A769662 (Figure S3), we examined
the dynamics of the enzyme in the presence and absence of
this ligand. HDX studies revealed that the binding of A769662
resulted in significant perturbation in all three subunits of
AMPK (Figures 3A and 3B). A closer look at these results demon-
strated a large degree of protection from deuterium exchange
in the substrate binding cleft of the a subunit kinase module,
particularly the Ca helix. Moreover, slight but significant protec-
tion was also observed in the activation loop peptides containing
the phosphorylated T172 while the equivalent nonphosphory-
lated peptide showed no degree of protection to exchange
(Table S1). Similar behavior was seen in the GBD of the b subunit
(Figures 3A and 3B). Here, we observed nearly the entire region
was protected from exchange when bound to A769662 including
the region encompassing the phosphorylated S108 residue,
which, similar to the T172 peptide in the a subunit, was not
protected in the absence of phosphorylation (Table S1). This is
consistent with previous observations that mutation of S108 toAll rights reserved
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Allosteric Modulation of AMPK Detected by HDXalanine rendered AMPK virtually insensitive to activation by
A769662 (Sanders et al., 2007). Finally, we observed an increase
in exchange in site 3 of the g subunit, which consists of peptides
spanning the antiparallel beta sheets of the AMP exchangeable
site (228–243; Figures 3A and 3B; Tables S1 and S2). All
together, these data indicate that the binding of A769662 to
AMPK leads to a stabilization of the protein indicated by reduced
dynamics in both the activation loop and GBD domain within
the a and b subunits and an increase in dynamics in site 3 of
the g subunit that contains an AMP exchangeable site. Most
importantly, this HDX profile shows that interaction of A769662
with AMPK leads to allosteric changes in the enzyme that
directly affect important sites known to be involved in enzyme
activation.
We next examined the protein dynamics of AMPK with beta-
cyclodextrin, a cyclic oligosaccharide known to bind to the b
subunit from X-ray crystallography studies (Polekhina et al.,
2005). When bound to beta-cyclodextrin, the a and g subunits
of AMPK showed no significant perturbation compared to
unliganded enzyme. As expected, we did observe protection
from deuterium exchange in the b subunit encompassing the
majority of the GBD (Figures 3A and 3B; Tables S1 and S2).
However, no protection was seen for peptides containing
S108 in either its phosphorylated or nonphosphorylated forms.
Instead, the greatest protection is seen in peptides containing
residues that are known to interact with glycogen (W100,
K126, W133, L146, and T148). Taken together, this profile
suggests that beta-cyclodextrin is capable of binding the b
subunit of AMPK but does not modulate the conformation
of the other subunits that contain key residues involved in
enzyme activation. This is consistent with previous observa-
tions that b cyclodextrin binds to AMPK but does not augment
or inhibit its catalytic activity (Bieri et al., 2012; Polekhina et al.,
2003).
We next investigated the protein dynamics of AMPK in the
presence of both A769662 and beta-cyclodextrin to determine
whether these ligands compete for binding or occupy different
binding sites on the enzyme. The protection profile observed in
the a subunit of AMPK with simultaneous addition of A769662
and beta-cyclodextrin was very similar to that obtained with
A769662 alone. Together, beta-cyclodextrin and A769662 pro-
tected the Ca helix, DFG-motif, and the activation and catalytic
loops of the a subunit to a similar extent as observed with
A769662 alone. In addition, the entire GBD of the b subunit
exhibited protection from exchange and showed differential
protection patterns around S108 depending on its precise phos-
phorylation state. Moreover, in the presence of both b cyclodex-
trin and A76962, we observed an additive effect for protection
from solvent exchange in peptide segments that are known to
be involved in interaction with glycogen. Taken together, the
pattern of protection observed when both of these ligands
were present was a combination of the patterns elicited by
each ligand individually. The only increase in magnitude of pro-
tection occurred in regions of known glycogen interactions
where both ligands individually showed protection compared
to the unliganded enzyme. This suggests that A769662 and
beta-cyclodextrin occupy different binding sites on the b sub-
unit. As observed with beta-cyclodextrin alone, very little pertur-
bation was observed in the g subunit on combined addition ofStructure 21, 1942–19A769662 and beta-cyclodextrin (Figures 3A and 3B; Tables S1
and S2).
We also interrogated the differential HDX profile of AMPK
bound to the known kinase inhibitor staurosporine. Protection
from exchange was observed in the ATP binding site (94–101),
catalytic loop (127–147), and the DFG motif (152–163), which
corresponds to the observed binding site of staurosporine in
the cocrystal structure (Xiao et al., 2011). No perturbation was
seen in the Ca helix or the activation loop and an increase in
deuterium exchange was observed in a helix (288–298) in the
auto-inhibitory region downstream of the catalytic module.
Moreover, no significant perturbation was observed in either
the b or g subunits (Figures 3A and 3B; Tables S1 and S2). The
deuterium exchange pattern of staurosporine shows that while
this promiscuous kinase inhibitor bound to previously identified
regions of the a subunit, there were no long-range effects
observed either on the activation loop of the kinase or the b/g
subunits. Moreover, the differences in the HDX fingerprints
between staurosporine and A769662 suggest that they share
nonoverlapping binding sites.
Probing Binding Mode: Effect of AMP and A769662
on Truncated AMPK
To further probe the binding sites of AMP and A769662, we used
a truncated AMPK reagent (AMPKt) similar to the trimeric com-
plex used for the crystallographic study of the first mammalian
AMPK structure (Xiao et al., 2007). While the entire g1 subunit
is present in the AMPKt construct, it contains only the C-terminal
portions of the a1 (405–557) and b1 (185–270) subunits. Subunits
were truncated to exclude the kinase module of the a subunit
and the GBD of the b subunit to determine if these ligands could
still interact with the enzyme that is devoid of these domains. The
differential HDX profile of AMPKt obtained with AMP revealed
significant protection around the AMP sites 3 and 4 on the g sub-
unit (Figures 4A and 4B; Table S2). In contrast, no perturbation
was observed for any of the peptides from the a or b subunit
upon binding of AMP. Moreover, comparable protection profiles
were observed for the exchangeable (site 3) and weakly
exchangeable (site 4) AMP binding sites (Figures 4A and 4B).
The degree of protection of AMPKt by AMP was less than that
observed for the full-length AMPK heterotrimer bound to AMP
(Table S2). This suggests that presence of other structural
modules of the a and b subunits contributes to the overall allo-
steric conformational dynamics of full-length AMPK. Incubation
of AMPKt with A769662 produced no significant HDX perturba-
tion in any of the subunits, suggesting that it no longer harbors
a binding site for the ligand (Figures 4A and 4B).
Effect of AMP and A769662 on AMPK a2b2g1: Negative
Control for A769662 Binding
To investigate the specificity of A769662 for b1-containing
AMPK isoforms, as has been reported in the literature (Sanders
et al., 2007; Scott et al., 2008), we studied the interaction of
A769662 and AMP with the a2b2g1 isoform. Several studies in
the literature have reported that AMP is a more potent activator
of a2b2g1 compared to the a1b1g1 isoform (Sanders et al.,
2007). In contrast, A769662 is a weak activator of b2-containing
AMPK (Sanders et al., 2007; Scott et al., 2008). Binding of AMP
resulted in protection of the Ca helix (60–70), ATP site (94–101),53, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1947
Figure 4. Effect of AMP and A769662 Binding on Truncated AMPK
(A) Differential HDX data mapped onto the AMPK atomic structure (PDB 2Y94).
(B) Schematic representation of AMPK regions undergoing conformational changes upon AMP/A769662 binding. Percentages of deuterium differences are
color-coded according to the color key. The boxed area in the activation loop region represents the phosphorylated form as compared to the nonboxed area
below that represents the nonphosphorylated form.
See also Figure S3 and Table S2.
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Allosteric Modulation of AMPK Detected by HDXcatalytic loop (127–147), the DFG module (152–163), and an AID
peptide (305–311) of the a subunit of the a2b2g1 isoform. Inter-
estingly, the differential HDX profile of AMPwith a2b2g1 is some-
what similar to what was observed on binding of A769662 to the
a1b1g1 isoform. Peptides in the activation loop containing the
phosphorylated T172 exhibited protection as well. Slight protec-
tion was also seen in the C-terminal portion of the b subunit (215–
243). In contrast, we observed significantly more protection
across a longer segment of the g subunit in a2b2g1 when
compared to the effect of AMP on the a1b1g1 isoform with
greater protection around the exchangeable AMP binding site
(3) than the weakly exchangeable site (Figures 5A and 5B; Tables
S1 and S2). The increased stabilization of AMPK a2b2g1 by AMP
in the g subunit where AMP binds as well as the important
regions for activation in the a and b subunits are consistent
with the observations that AMP is a more potent activator of
a2b2g1. Upon binding of A769662, we observed similar levels
of protection induced in the kinase module of a2b2g1 as was
observed in the differential HDX experiments with a1b1g1 iso-
form (Figures 5A and 5B; Tables S1 and S2). However, slightly
different peptides in the AID regions of the two isoforms were
perturbed on binding of A769662. While the peptide 288–2981948 Structure 21, 1942–1953, November 5, 2013 ª2013 Elsevier Ltdof the a1 subunit was stabilized by A769662; in the a2 subunit,
a nearby peptide 305–311 showed a similar magnitude of
stabilization. The significance of these subtle differences in the
conformational dynamics of the two a subunits is unclear at
present. Interestingly, significant protection was seen across
most of the GBD of the b subunit, but no perturbation was
observed for peptides containing S108 irrespective of the
phosphorylation state. This indicated that while A769662 still
bound to a2b2g1, it did not have the same role in activation of
the b2-containing AMPK isoform. It further suggests that for
A769662 to activate AMPK, it binds to the b subunit in such
a way as to directly stabilize the S108 phosphorylation site
(on the b subunit) and also allosterically stabilize the activation
loop and T172 site within the a subunit.
DISCUSSION
In this study we applied HDX coupled with mass spectrometry
to probe the protein dynamics of AMPK in the absence and
presence of activators and inhibitors to better understand the
allosteric conformational changes involved in activation of this
master metabolic regulator. These HDX studies reveal allostericAll rights reserved
Figure 5. Effect of AMP and A769662 Binding on AMPK a2b2g1 Isoform
(A) Differential HDX data mapped onto the AMPK atomic structure (PDB 2Y94).
(B) Schematic representation of AMPK regions undergoing conformational changes upon AMP/A769662 binding. The percentage of deuterium differences are
color-coded according to the color key. The boxed area in the activation loop region represents the phosphorylated form as compared to the nonboxed area
below that represents the nonphosphorylated form.
See also Figure S3 and Tables S1 and S2.
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Allosteric Modulation of AMPK Detected by HDXcommunication across subunits of the heterotrimeric kinase
trigged by the binding of small molecule ligands and point to
the molecular binding site of A769662 on AMPK. These data
also strongly suggest two fundamentally different modes of
AMPK activation by the nucleotides and A769662 (summarized
in Figure 6). These data could provide a potential framework
for the design and discovery of isoform-specific AMPK activa-
tors for the treatment of metabolic diseases.
To perform these studies using our automated HDX-MS plat-
form, we followed more than 500 peptides of heterotrimeric
AMPK (134 kDa). First, we evaluated the differences in protein
dynamics of apo AMPK (unliganded or free enzyme), specifically
to examine the effect of phosphorylation on two important sites
crucial for the activation of the enzyme, T172 (a subunit) and
S108 (b subunit). Phosphopeptides around these two sites dis-
played attenuated dynamics compared to their unphospho-
rylated counterparts. This is consistent with the notion that
phosphorylation of the activation loop of the a subunit and the
S108 loop of the b subunit promotes amore stable conformation.
In addition, we observed that the dynamics between the
exchangeable and nonexchangeable AMP sites within the CBS
domains of the g subunit were significantly different in theStructure 21, 1942–19unliganded enzyme. The exchangeable AMP site (site 3) clearly
exhibited enhanced dynamics while the nonexchangeable
AMP site (site 4) was much more stable. This suggests that the
AMPK site 3 could have a more functional role in the activation
mechanism of AMPK compared to site 4.
We then evaluated a number of known AMPK activators and
inhibitors to see whether HDX profile could give new insights
into the activationmechanism. Strong protection from deuterium
exchange in the CBS domains of the g subunit was elicited by
AMP and its analog, ZMP (AICAR metabolite). Because the g
subunit harbors the known AMP binding sites (exchangeable
and nonexchangeable), it is not surprising that binding of these
ligands to AMPK would lead to a stabilization of the dynamics
of this region. We observed only limited perturbations on the
a or b subunits on binding of AMP and ZMP with slightly
enhanced effect observed for AMP. This is most likely a reflec-
tion of the enhanced binding affinity of AMP for AMPK compared
to ZMP and not suggestive of any differences in their activa-
tion mechanisms. We next investigated the HDX profile of
A769662, the well-studied thienopyridone synthetic activator
(Figure S3; Cool et al., 2006). Upon binding of A769662, there
were decreases in dynamics of the activation loop and pT17253, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1949
Figure 6. Schematic of AMPK Confor-
mational Dynamics Induced by Different
Activators
Protein stabilization caused by ligand binding
(as measured by the differential HDX profile) is
shown in blue, whereas destabilization is shown
in yellow. Changes in stabilization are a result of
altered conformation of the protein. Known or
putative ligand binding sites on AMPK subunits
are shown by orange squares (AMP), dark circles
(ZMP), green triangles (A769662), and solid stars
(beta-cyclodextrin). These are just schematic
representations of the general observations from
the HDX experiments with different ligands but
not an absolute mapping of the extent of deute-
rium exchange. AMP binding results in enhanced
protection or stabilization of the g subunit and
the activation loop in the kinase module of the a
subunit. Binding of ZMP, an AMP analog and a
cellular metabolite of AICAR, primarily alters the
HDX profile in the g subunit and to a smaller
extent, the a subunit. The synthetic activator
A769662 displays strong stabilization of the b
subunit and portions of the a subunit involved
in substrate binding and catalysis. In addition,
A769662 causes destabilization of the g subunit,
the reasons for which are not completely under-
stood. The effect of the glycogen mimetic, beta-
cyclodextrin, is mostly restricted to the b subunit.
The combination of A769662 and beta-cyclodex-
trin elicits a profile that is a combination of the
individual profiles obtained by each of the ligands.
These results also suggest that A769662 and
beta-cyclodextrin bind at nonoverlapping sites on
the glycogen binding module of the b subunit. The
HDX data strongly suggest two fundamentally
different modes of AMPK activation by A769662
and the nucleotides.
Structure
Allosteric Modulation of AMPK Detected by HDXof the a subunit as well as most of the GBD module in the b sub-
unit, including pS108. Moreover, there was increased dynamics
observed in the g subunit around the exchangeable AMP binding
site (site 3). Thus, binding of A769662 induces a conformation
that stabilizes regions containing both phosphorylation sites
known to be important for activation and clearly displays allo-
steric effects across all three subunits. Some of the changes
observed in the deuterium exchange profile such as those occur-
ring in the activation loop of the a subunit can be attributed to
conformational changes caused by the binding of the ligand. In
contrast, the decreased dynamics observed in the GBD of the
b subunit most likely reflects additive effects of conformational
changes and those caused by direct binding of A769662 to the
GBD module. However, it is unclear how binding of A769662
near the GBD module leads to perturbations in the g subunit.
There are conflicting reports in the literature on how glycogen
modulates the activity of AMPK. Earlier studies showed essen-
tially no effect on AMPK activity upon binding of glycogen (Pole-
khina et al., 2003). Subsequent studies with small, branched
oligosaccharides showed modest inhibition of AMPK activity
(McBride et al., 2009). In our HDX-MS studies, addition of
beta-cyclodextrin, a cyclized form of maltoheptaose, resulted
in significant stabilization of the GBDmodule of AMPK b subunit.
These results are consistent with previous reports that beta-1950 Structure 21, 1942–1953, November 5, 2013 ª2013 Elsevier Ltdcyclodextrin binds to the GBD module of AMPK (Polekhina
et al., 2005). However, we observed no allosteric effects of
beta-cyclodextrin on any of the important regions required for
activation in either the a or g subunit. This suggested that
AMPK harbors a binding site for beta-cyclodextrin but is neither
activated nor inhibited by it. Staurosporine, which is a well-
known kinase inhibitor, displayed changes in dynamics of the
a subunit around the ATP binding site nearly exclusively with
very little allosteric effects seen in the b or g subunits. This is
consistent with previous crystallographic observations of the
binding of staurosporine at the ATP site of AMPK (Xiao et al.,
2011).
Ever since the discovery of A769662 as a direct AMPK acti-
vator, there has been considerable interest in deciphering its
exact binding site on AMPK. The differential HDX experiments
with A769662 described above demonstrated increased stabili-
zation of the a and b subunits caused by ligand binding. To more
precisely map the binding site of A769662, we analyzed the HDX
profile of AMPK bound to both A769662 and beta-cyclodextrin.
Combined addition of these two ligands elicited an HDX-MS
profile that is a combination of the two individual profiles. The
only region where we observed an increase in protein dynamic
stability in the presence of both ligands was the GBD of the b
subunit, indicating that A769662 bound within the b subunitAll rights reserved
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Allosteric Modulation of AMPK Detected by HDXbut in a different location than that of beta-cyclodextrin. This
conclusion was further strengthened when we observed that
a truncation construct of AMPK, which lacks the GBD and a
large portion of the a subunit, was completely unable to interact
with A769662. Furthermore, a2b2g1 AMPK isoform, which is
not known to be activated by A769662, displayed weaker
stabilization of the b subunit compared to the a1b1g1 isoform
and specifically did not show any stabilization of the S108 phos-
phorylation site within the GBD of the b subunit. Moreover, all
allosteric communication with the g subunit appeared to be
lost when A769662 bound to this b2-containing AMPK isoform.
These results suggest that A769662 functions as an activator
by binding directly to the GBD domain in the b subunit, specif-
ically stabilizing the S108 phosphorylation site that then leads
to allosteric changes to the a and g subunits that activate the
enzyme fully. These results are also consistent with previous
observations that either mutation of Ser108 of the b subunit
to alanine or truncation of the GBD module renders AMPK
completely insensitive to activation by A769662 or salicylate
(Hawley et al., 2012; Sanders et al., 2007; Scott et al., 2008).
The downstream biology elicited following activation of
AMPK can differ from one tissue to another depending on the
AMPK isoforms that are expressed and their protein substrates.
Moreover, the precise conformational changes induced on
AMPK following stimulation by endogenous ligands or pharma-
cological agents can alter the response further. Comparison of
the HDX-MS profiles of a1b1g1 versus a2b2g1 show that AMP
has a more profound effect on the dynamics of the g subunit in
the latter (Table S2). Although both isoforms contain the same
g subunit where AMP binds, the increased protection observed
in the g subunit of the a2b2g1 isoform suggests a possible role
for a and b subunits. This could also reflect the increased binding
affinity of AMP for a2b2g1 compared to a1b1g1. In addition,
AMP has a larger effect in protection (from deuterium exchange)
of some peptides from the a and b subunits of a2b2g1 compared
to a1b1g1, consistent with its enhanced potency in biochemical
activation of the former. Taken together, these results support
observations that nucleotide binding has effects that extend
beyond the g subunit.
Although the synthetic activator A769662 is known to be a
b1-specific activator, its differential HDX profile with a2b2g1
shows clear evidence for binding and conformational changes.
It induces similar conformational changes on the a subunits of
a1b1g1and a2b2g1 but a drastically different profile on the b
subunits (Table S2). The HDX profiles suggest that A769662
binds near the GBD modules of both a1b1g1 and a2b2g1 iso-
forms, consistent with previous biochemical reports (Hawley
et al., 2012; Sanders et al., 2007). This is further supported by
the absence of any significant conformational changes upon
addition of A769662 to a truncated a1b1g1 construct that
lacks the GBD and kinase modules (Table S2). Conformations
of different regions of the GBD modules of a1b1g1 and a2b2g1
are affected by A769662, which suggests that it binds at
two distinct sites on the two b subunits. Whereas binding
of A7669662 leads to conformational changes around the
pSer108 site in the b1 subunit, it is the beta-cyclodextrin binding
site that is perturbed in the b2 subunit.
As a master regulator of metabolism, AMPK needs to quickly
respond to changes in the cellular energy status. This requiresStructure 21, 1942–19long-range communication between catalytic and regulatory
domains. Through the application of HDX-MS technology, we
have probed the intrinsic flexibility of different segments of
AMPK and the changes induced by ligand binding. These HDX
studies measure allosteric communication across subunits of
the heterotrimeric kinase trigged by the binding of small mole-
cule ligands and provide additional insight into the molecular
binding site of A769662 on AMPK. These data also strongly
suggest two fundamentally different modes of AMPK activation
by the nucleotides and A769662 (summarized in Figure 6).
EXPERIMENTAL PROCEDURES
Cloning of Full-Length Human AMPK Complex for Bacterial
Expression
A tricistronic construct that included open reading frames encoding the full-
length a, b, and g subunits of human AMPK was designed with a ribosome-
binding site (RBS) ahead of each coding region (Neumann et al., 2003;
Rajamohan et al., 2010). The construct was custom-synthesized with codons
optimized for bacterial expression (GENEART). The 22-residue N-terminal tag
of the a subunit included six histidine residues and a cleavage site for thrombin
(MGSSHHHHHHSSGLVPRGSMGT). The tricistronic construct was subcloned
into the NcoI and XhoI sites of pET-14b expression vector (Novagen) using
standard molecular biology techniques (Maniatis and Sambrook, 1982).
Similar protocols were used for the expression, purification, and characteriza-
tion of a1b1g1, a2b2g1, and a1b1g1t AMPK reagents.
Expression and Purification of Recombinant AMPK Complex
from Escherichia coli
AMPK tricistronic construct was transformed into E. coli BL21-CodonPlus
(DE3)-RIPL strain (Stratagene) and transformants were selected on LB
(Luria-Bertani) agar plates containing ampicillin (100 mg/ml). Single colonies
were used to inoculate 10 ml of LB medium containing 100 mg/ml ampicillin.
For large-scale expression and purification, an Erlenmeyer flask containing 1
l of LB broth supplemented with 100 mg/ml ampicillin was inoculated with
25ml of overnight culture and grown in a shaker incubator at 37C to an optical
density 600 (OD600) of 0.8. Protein expression was induced with 100 mM
(final concentration) of isopropyl b-D-thiogalactopyranoside (IPTG), the
temperature was reduced to 18C, and the cells were grown for an additional
18 hr. Cells were harvested and resuspended in 50 ml lysis buffer (50 mM Tris,
pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM Tris-2-carboxyethyl phosphine
[TCEP], 20 mM imidazole and 0.001% Triton X-100). The cell suspension
was sonicated on ice with a Branson ultrasonic disintegrator (VWR Scientific
Products) for 2–4 min at 50% duty cycle. Insoluble material was removed by
centrifugation at 15,000 rpm in a Sorvall RC5 plus centrifuge for 30 min at
4C and the supernatant was loaded onto a 5 ml HisTrap HP column (GE
Healthcare) and washed with five column volumes of lysis buffer. Bound
proteins were eluted using a linear gradient (ten column volumes) with elution
buffer (lysis buffer containing 300 mM imidazole). Fractions containing AMPK
subunits were pooled based on SDS-10% PAGE analysis and dialyzed over-
night in dialysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 10% glycerol,
2 mM TCEP, and 0.001% Triton X-100). The AMPK complex was further
purified by gel filtration chromatography with a Superdex 200 HiLoad 16/60
column (GE Healthcare) in SEC buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
10% glycerol, 2 mM TCEP, and 0.001% Triton X-100).
Activation of AMPK Heterotrimer
To determine the relevant amount of upstream kinase to be used in the
phosphorylation reaction, the AMPK complex was incubated with increasing
concentrations of upstream kinases and the concentration of upstream kinase
that yielded the highest possible level of Thr172 (a2-subunit) phosphorylation
was used in the subsequent reactions. To evaluate which upstream kinase
was more effective at phosphorylating residue Thr172, 1.0 mM Ni2+-column
purified AMPK complex was incubated in the presence or absence of
200 nM upstream AMPK kinase (CaMKKb or LKB; The University of Dundee,
Scotland) in 100 ml of phosphorylation buffer (25 mM Tris, pH 7.5, 137 mM53, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1951
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calmodulin) for 30 min at 30C in a thermostated shaker. The reaction was
stopped by freezing the samples at 80C. Activation of Ni-purified recombi-
nant AMPK heterotrimeric complexes was performed by incubating 1.0 mM
AMPK complex in the presence of 200 nM CaMKKb in phosphorylation buffer
for 30 min at 30C in a thermostated shaker. The phosphorylated AMPK com-
plex was repurified on HisTrap HP column as before and dialyzed overnight
in dialysis buffer. The phosphorylated AMPK complex was further purified
by gel filtration chromatography with a Superdex 200 HiLoad 16/60 column
(GE Healthcare) in SEC buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 10%
glycerol, 2 mM TCEP, and 0.001% Triton X-100). The final samples were
stored at 20C with 25% glycerol. Characterization by mass spectrometry
showed that the recombinant enzyme is phosphorylated on Thr172 of
the a subunit and Ser108 of the b subunit with no myristoylation on the
b subunit.
Hydrogen/Deuterium Exchange Mass Spectrometry
Differential, solution phase HDX experiments were performed with a fully
automated system using a LEAP Technologies Twin HTS PAL liquid
handling robot interfaced to an Exactive Orbitrap mass spectrometer
(Thermo Scientific, Bremen, Germany; Chalmers et al., 2006). Each ex-
change reaction was initiated by incubating 4 ml of protein (with or without
ligand) with 16 ml of D2O protein buffer for a predetermined time (10 s, 30
s, 60 s, 300 s, 900 s, and 3,600 s in a randomized order) at 4C. The ex-
change reaction was quenched by mixing the protein solution with 30 ml
of 3 M urea, 1% TFA at 1C. The mixture was passed across an in-house
packed pepsin column (1 mm 3 20 mm) at 50 ul/min and digested peptides
were captured onto a 1 mm 3 10 mm C8 trap column (Thermo Scientific)
and desalted (total time for digestion and desalting was 2.5 min). Peptides
were then separated across a 1 mm 3 50 mm C18 column (5 mm Hypersil
Gold, Thermo Scientific) with linear gradient of 5%–50% CH3CN, 0.3%
formic acid, over 5 min. Protein digestion and peptide separation were
performed within a thermal chamber (Me´cour) held at 15C and 1C,
respectively, to promote more efficient digestion and to reduce D/H back
exchange. Electrospray ionization parameters were set as the following:
sheath gas 30 au, auxiliary gas 15 au, spray voltage 3.7 V, capillary temper-
ature 225C, capillary voltage 25 V, tube lens 95 V, skimmer 16 V. Mass
spectrometric analyses were acquired with a measured resolving power of
100,000 at m/z 400. Three replicates were performed for each ion-exchange
time point.
Peptide Identification and HDX Data Processing
MS/MS experiments were performed with a FinniganLTQ linear ion trap
mass spectrometer (Thermo Electron). Product ion spectra were acquired in
a data-dependent mode and the five most abundant ions were selected for
the product ion analysis. The MS/MS *.raw data files were converted to
*.mgf files and then submitted to Mascot (Matrix Science) for peptide iden-
tification. Peptides included in the peptide set used for HDX had a MASCOT
score of 20 or greater. The MS/MS MASCOT search was also performed
against a decoy (reverse) sequence and ambiguous identifications were
ruled out. The MS/MS spectra of all the peptide ions from the MASCOT search
were further manually inspected and only those verifiable were used in the
coverage. The intensity weighted average m/z value (centroid) of each peptide
isotopic envelope was calculated with the latest version of our in-house
developed software, MS Peptide Workbench.
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